National Law Review (Polsinelli PC) was explicit on April 22, 2026: removing a Category 2 bulk drug substance does not, on its own, authorize use of that substance in compounding or bring it within FDAs interim enforcement discretion policy for substances in Category 1. Even Category 1 substances are only under enforcement discretion, which is short of full authorization
Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 agonist
Protect from excessive heat and environmental contamination
In chronic plantar fasciitis, this organization becomes disrupted, with collagen fibers losing their alignment and the tissue becoming thickened yet weaker
Molecular features of the ligand-free GLP-1R, GCGR and GIPR in complex with G(s) proteins
Research suggests that GLP-1 may have neuroprotective effects, potentially influencing brain health and cognitive function